Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Methodist Hospital Research Institute
This is a single-arm pilot study assessing the feasibility and efficacy of EA in 20 subjects with CIPN. The primary objective is to determine the feasibility of a 10-treatment EA program in subjects with CIPN. Feasibility will be defined as ≥15 patients completing ≥8 EA treatments. Secondary objectives include change in neuropathic pain and quality of life before and after EA treatment. An exploratory correlative analysis of mechanistic biomarkers will also be performed.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female aged ≥18 years
Received curative-intent chemotherapy (i.e., paclitaxel, docetaxel, nab-paclitaxel, carboplatin, oxaliplatin, vinorelbine, ixabepilone, or vincristine) ≥3 months prior to the start of EA treatment
Persistent Grade ≥2 peripheral neuropathy in the fingers or toes according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0
Eastern Cooperative Oncology Group performance status of ≤2 (see Section 13.3)
Willing and able to provide written informed consent for the study.
You may not be if
Documented medical history of neuropathy resulting from nerve compression (e.g., carpal tunnel syndrome, radiculopathy, or spinal stenosis)
Severe coagulopathy or bleeding disorder, per the treating physician's discretion
Presence of cellulitis or other skin infection or condition that would preclude placement of acupuncture needles into the hands or feet
Diabetes unless Hgb A1c \<7.5%
Unstable cardiac disease
Pacemaker
Metal plates
Known psychiatric disorder that would interfere with cooperation with the requirements of the study
